Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 8/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.52 |
| ▸ | F10 | P00742 | 11/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 7/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | C1S | P09871 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4744355 | 0.80 | EPHX1 (0.42) | — | |
| SCHEMBL9030495 | 0.76 | F2 (0.53) | PRSS1F10F2PLAUPLG | |
| SCHEMBL8555997 | 0.75 | PRSS1 (0.47) | PRSS1PRSS2PRSS3F10LOXL2 | |
| SCHEMBL28426292 | 0.75 | PRSS1 (0.56) | PRSS1PRSS2PRSS3F10LOXL2 | |
| SCHEMBL9030444 | 0.74 | PRSS1 (0.48) | PRSS1PRSS2PRSS3F10F2 | |
| SCHEMBL288337 | 0.72 | SLC7A5 (0.65) | PRSS1PRSS2PRSS3LOXL2 | |
| SCHEMBL202409 | 0.72 | SLC7A5 (0.65) | PRSS1PRSS2PRSS3LOXL2 | |
| SCHEMBL31538733 | 0.72 | SLC7A5 (0.65) | PRSS1PRSS2PRSS3LOXL2 | |
| SCHEMBL202408 | 0.72 | SLC7A5 (0.65) | PRSS1PRSS2PRSS3LOXL2 | |
| SCHEMBL8173801 | 0.70 | F7 (0.47) | PRSS1PRSS2PRSS3F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832076-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |